Total
0
Shares
Volpara Health Technologies (ASX:VHT) - CEO, Dr Ralph Highnam
CEO, Dr Ralph Highnam
Source: Volpara Health Technologies
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Volpara Health Technologies (VHT) has signed its highest value contract to date though recently acquired subsidiary CRA Health
  • The contract is worth over US$400,000 (roughly A$513,000) per year in annual recurring revenue
  • The contract covers the provision of breast cancer risk scores to a large Indiana-based organisation that has sites across more than 20 U.S. states
  • Volpara’s CEO says the contract will enable VHT to help more women across the United States benefit from early cancer detection and sets the company up for future sales of additional products
  • Volpara Health Technology is up 7.22 per cent, trading at $1.41

Volpara Health Technologies (VHT) has signed its highest value contract to date though recently acquired subsidiary CRA Health.

Volpara forked out over $23 million to buy Boston-based breast cancer risk assessment company CRA Health in February this year.

The purchase gave Volpara access to CRA’s cloud-based breast cancer assessment software, which the company considered to be highly complementary to Volpara’s own medical breast imaging and analytics technology.

The contract, worth over US$400,000 (roughly A$513,000) per year in annual recurring revenue, covers the provision of breast cancer risk scores to a large Indiana-based organisation that has sites across more than 20 U.S. states.

The unnamed organisation also runs a major electronic health record system.

“We are very pleased to announce that CRA Health has signed up a major US health system with significant ARR associated with it,” said Volpara Group CEO, Dr Ralph Highnam.

“Whilst we would not normally announce individual deals, this is the Volpara Group’s highest value contract signed to date. Not only does it enable us to help many more women across the United States benefit from early cancer detection, but it also sets us up for future sales of additional products to this organisation.”

“Further, the contract is validation of the decision to purchase CRA Health and validation that the world is rapidly moving towards personalised breast care, which includes analysis of risk and genetics.”

Volpara Health Technology is up 7.22 per cent, trading at $1.41 at 12:30 pm AEDT.

VHT by the numbers
More From The Market Herald
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp Health (ASX:RAP) achieves regulatory approvals for cough counter application

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.